ライフサイエンスコーパス: brachial

1 All infusions were intra-arterial (brachial).

2 Brachial and aortic BP was lower in controls than in CKD

3 We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial

4 in order to achieve functional repair after brachial and lumbosacral plexus avulsion injuries.

5 Both A (radial/brachial) and B (axillary/subclavian/innominate) variant

6 evaluate the role of large artery stiffness, brachial, and central blood pressure as predictors of in

7 d standard index of large artery stiffness), brachial, and central pressures (estimated via radial to

8 stiffness indices, in particular of carotid, brachial, and femoral stiffness, with cardiovascular dis

9 Brachial-ankle pulse wave velocity (baPWV) was measured

10 Brachial-ankle PWV was significantly higher among Abeta-

11 , peripheral (femoral-ankle PWV), and mixed (brachial-ankle PWV) vascular beds.

12 asures, and the high sodium visit included a brachial arterial catheter for forearm vasodilator respo

13 e evaluated the association of early optimal brachial arterial dilatation with a successful AVF matur

14 f peribrachial adipose tissue in determining brachial arterial distensibility.

15 nal Doppler ultrasound was used to determine brachial arterial endothelial function.

16 sed local stiffness of carotid, femoral, and brachial arteries (by ultrasonography), carotid-femoral

17 inly rely on blood pressure (BP) measured at brachial arteries (cuff BP).

18 al, popliteal (treated with stretching), and brachial arteries (untreated) of both sides.

19 Brachial arteries of athletes were larger (Athletes 5.39

20 Elite power athletes have larger brachial arteries, and greater vasoreactivity (greater v

21 lved (femoral and popliteal) and uninvolved (brachial) arteries.

22 hemia induced by a surgical occlusion of the brachial artery (BAO) induces increased paw-guarding beh

23 and autologously transfused into the forearm brachial artery 5 and 42 days after blood donation.

24 by measuring changes in the diameter of the brachial artery after 5 minutes of arterial occlusion.

25 y) for 45 min with catheters inserted in the brachial artery and both femoral veins.

26 ressed by a smaller percentage of FMD of the brachial artery and higher salivary levels of MMP-2/TIMP

27 Blood was sampled simultaneously from the brachial artery and internal jugular and femoral veins w

28 essed by flow-mediated dilation (FMD) of the brachial artery and TR jet velocity, respectively.

29 Immediate left brachial artery angiography with subsequent thrombectomy

30 ood pressure, mean arterial pressure (MAP)], brachial artery blood flow ( Q (BA) ), FVC ( Q (BA) /MAP

31 croneurography), arterial blood pressure and brachial artery blood flow (duplex Doppler ultrasound) w

32 am), oxygen saturation (pulse oximetry), and brachial artery blood flow and shear rate (ultrasound) w

33 We assessed brachial artery blood flow during maximal handgrip exerc

34 he assessment of endothelial function in the brachial artery by flow-mediated dilatation (FMD).

35 s (IMT), flow-mediated vasodilatation of the brachial artery by ultrasound, assessment of endothelial

36 he assessment of endothelial function in the brachial artery by using flow-mediated dilation.

37 (r = -0.301, p = 0.008), and the presence of brachial artery calcification (r = -0.178, p = 0.036).

38 n alpha1 -adrenoceptor agonist) infusion via brachial artery catheter in response to two different st

39 alpha- and beta-adrenoceptor blockade (via a brachial artery catheter) to eliminate sympathoadrenal i

40 therapy were not apparent from conventional brachial artery cuff pressure assessments.

41 Before and after each exposure, brachial artery diameter (BAd) was assessed using ultras

42 Brachial artery diameter (BAD) was measured by ultrasoun

43 nd P = 0.005, respectively) alongside larger brachial artery diameter (P = 0.015) and lower FMD perce

44 blood pressure, heart rate, and simultaneous brachial artery diameter and blood velocity were recorde

45 Brachial artery diameter, a predictor of cardiovascular

46 esolution ultrasonography was used to assess brachial artery diameters at rest and following 5 minute

47 It was hypothesized brachial artery diameters of athletes would be larger, h

48 erformed at 1 month after surgery, and early brachial artery dilation was defined as the change in po

49 effect of a low-fat spread with added PSs on brachial artery endothelial function as measured by flow

50 Brachial artery endothelial function, pulmonary function

51 Cardiovascular profiles, brachial artery endothelial-dependent flow-mediated dila

52 Higher resting brachial artery flow (OR, 1.23 [95% CI, 1.04-1.46]) and

53 nd following 5 minutes of forearm occlusion (Brachial Artery Flow Mediated Dilation = BAFMD) and a co

54 ous and venous plasma carnitine difference x brachial artery flow), and carnitine disappearance (Rd)

55 Endothelial function assessed by brachial artery flow-mediated dilatation (FMD) was measu

56 in [Hb] and haematocrit (Hct) would increase brachial artery flow-mediated dilatation (FMD).

57 systemic vasculature was investigated using brachial artery flow-mediated dilatation and carotid art

58 ic haemodilution led to a marked increase in brachial artery flow-mediated dilatation in humans The i

59 ve was to quantify endothelial function (via brachial artery flow-mediated dilatation) at sea level (

60 ve was to quantify endothelial function (via brachial artery flow-mediated dilatation) at sea level (

61 hed non-smoking control subjects we examined brachial artery flow-mediated dilation (FMD) and circula

62 we measured plasma nicotine, exhaled CO, and brachial artery flow-mediated dilation (FMD) before and

63 ndpoint was the week 24 within-arm change in brachial artery flow-mediated dilation (FMD) in particip

64 was reconstructed by mathematical modeling; brachial artery flow-mediated dilation (FMD) was measure

65 Brachial artery flow-mediated dilation (FMD), urinary 8-

66 Endothelial function was evaluated by brachial artery flow-mediated dilation (FMD).

67 Primary endpoints were safety and brachial artery flow-mediated dilation (FMD).

68 ammatory markers and vascular function using brachial artery flow-mediated dilation (FMD).

69 Coprimary end points included change in brachial artery flow-mediated dilation (FMDBA) and aorti

70 ly 50% (to 70 +/- 30 mmol/day), and conduit (brachial artery flow-mediated dilation [FMD(BA)]) and re

71 mary end point was change in maximal percent brachial artery flow-mediated dilation after exposure.

72 ignificantly increased endothelium-dependent brachial artery flow-mediated dilation at 16 weeks, wher

73 outcome was change in endothelium-dependent brachial artery flow-mediated dilation at 16 weeks.

74 er high-density lipoprotein cholesterol, and brachial artery flow-mediated dilation compared with lea

75 Bruce protocol), applanation tonometry, and brachial artery flow-mediated dilation testing.

76 nded particles, the absolute maximal percent brachial artery flow-mediated dilation was reduced by 0.

77 Brachial artery flow-mediated dilation, 24-hour urinary

78 scular dysfunction, as evidenced by impaired brachial artery flow-mediated dilation, abnormal cerebra

79 We measured vascular endothelial function by brachial artery flow-mediated dilation.

80 Primary endpoints were changes in brachial artery flow-mediated vasodilation (FMD), caroti

81 The primary outcome was the change in brachial artery flow-mediated vasodilation (FMD).

82 However, brachial artery FMD (ET: 3.8 +/- 3.0% vs. CT: 4.3 +/- 3.

83 Peak Vo2, brachial artery FMD in response to cuff ischemia, caroti

84 Brachial artery FMD increased by ~160% from 3.8 +/- 2.1

85 ntervention induced significant decreases in brachial artery FMD of all groups (P < 0.05).

86 P < 0.05) in femoral Delta Q , popliteal and brachial artery FMD%, respectively, occurred in both PS

87 Brachial artery FMD, carotid-femoral PWV, central AIx, a

88 ughout each exercise bout and in response to brachial artery FMD, measured prior to, immediately afte

89 s evaluated by flow-mediated dilation of the brachial artery in vivo and by vasomotor studies in saph

90 Flow-mediated dilatation of the brachial artery increased in the intervention group as c

91 (compared with <10%) significantly improved brachial artery macrovascular flow-mediated vasodilation

92 was measured by ultrasound before and after brachial artery occlusion [i.e., flow-mediated dilation

93 en consumption in the thenar eminence during brachial artery occlusion in sickle cell patients and he

94 essed by flow-mediated dilation (FMD) of the brachial artery preexposure, immediately postexposure, a

95 thickness (a measure of arterial stiffness), brachial artery reactivity (both flow-mediated dilatatio

96 ociated with carotid intima-media thickness, brachial artery reactivity-glycerol trinitrate, serum ur

97 greater retrograde shear likely modulate the brachial artery response, but the reduced total shear al

98 we conducted a novel assessment of vascular brachial artery responses both to ambient pollution and

99 Central haemodynamics, brachial artery shear rate (SR) and blood flow profiles

100 ned from the right internal jugular vein and brachial artery to determine concentration differences f

101 FMD and BAD were measured by brachial artery ultrasound at the initial examination of

102 and baseline arterial diameter (BAD) of the brachial artery using ultrasound in a large multicity co

103 After 30 minutes of rest, brachial artery vascular function was assessed by ultras

104 Flow-mediated dilation of the brachial artery was 25% smaller in ART than in control c

105 Following recovery, the brachial artery was cannulated and flushed with 10 000 U

106 ated endothelium-dependent relaxation of the brachial artery with doses of quercetin ranging from 50

107 lood pressure, flow-mediated dilation in the brachial artery, and carotid to radial pulse wave veloci

108 sured as flow-mediated dilation (FMD) of the brachial artery, has not been systematically assessed be

109 S AND RESULTS: Flow-mediated dilation of the brachial artery, matrix metalloproteinase-2 and matrix m

110 ssed systemic (flow-mediated dilation of the brachial artery, pulse-wave velocity, and carotid intima

111 maging and cuff pressure measurements in the brachial artery.

112 -induced flow-mediated dilation (FMD) of the brachial artery.

113 essed by flow-mediated dilation (FMD) of the brachial artery.

114 ans of flow-mediated dilatation (FMD) of the brachial artery.

115 t, we assessed (1) flow-mediated dilation of brachial artery; (2) coronary flow reserve, ejection fra

116 Besides the known effect of RD on brachial blood pressure, the study showed for the first

117 smography (PVP) waveform and calibrate it to brachial BP levels estimated with population average met

118 ient-specific method was applied to estimate brachial BP levels from a cuff pressure waveform obtaine

119 a ensemble averaging and calibrate it to the brachial BP levels.

120 The study was to explore whether the brachial/carotid pulse pressure (B/C-PP) ratio selective

121 goal was to evaluate the effects of MetS on brachial central pulse pressure (PP), PP amplification,

122 Brachial circumference (BC), also known as upper arm or

123 These differences are not identifiable using brachial cuff pressures.

124 , 1.12; 95% CI, 0.99-1.27; P=0.06), baseline brachial diameter (HR, 1.09; 95% CI, 0.90-1.31; P=0.39),

125 However, obese children had greater brachial diameters and resting and hyperemic blood flow,

126 of an alternative ABI method and use of the brachial difference identifies individuals at an increas

127 ess was an independent determinant for early brachial dilatation (beta = -0.286, p = 0.013).

128 interplay between the peri-brachial fat and brachial dilatation can be translated into novel clinica

129 Patients with a brachial dilatation greater than median level showed a 1

130 Interestingly, the early brachial dilatation showed significant correlations with

131 patients, and they had a significantly lower brachial dilatation than patients with successful AVF du

132 To evaluate the degree of brachial dilatation, follow-up US was performed at 1 mon

133 tion of sensory axons to the brainstem after brachial dorsal root crush in adult rats.

134 Brachial endothelial function did not differ between sea

135 A close interplay between the peri-brachial fat and brachial dilatation can be translated i

136 ignificantly associated with common carotid, brachial, femoral arterial parameters (lumen diameter [L

137 ean arterial pressure (P=0.04), and baseline brachial flow (P=0.002) were positively associated with

138 graphic factors, comorbidities, and baseline brachial flow volume, peribrachial fat thickness was an

139 f nitric oxide as a key regulatory factor of brachial flow-mediated dilatation and highlight the impo

140 Other outcomes (brachial flow-mediated dilatation, microvascular reactiv

141 <25th percentile, absence of carotid plaque, brachial flow-mediated dilation >5% change, ankle-brachi

142 he highest increment (0.623 vs 0.784), while brachial flow-mediated dilation had the least (0.623 vs

143 ment with coronary artery calcium was 0.659, brachial flow-mediated dilation was 0.024, ankle-brachia

144 Carotid intima-media thickness and brachial flow-mediated dilation were not associated with

145 ntima-media thickness, ankle-brachial index, brachial flow-mediated dilation, high-sensitivity C-reac

146 retic peptide) levels, cardiac output/index, brachial flows (ipsilateral to AVF), and pulmonary arter

147 edian CD4(+) count was 561 cells/microL, and brachial FMD was 4.2%.

148 ients) with critical limb ischemia and ankle brachial index >/=1.4 who underwent lower extremity angi

149 ial flow-mediated dilation >5% change, ankle-brachial index >0.9 and <1.3, high-sensitivity C-reactiv

150 sted after excluding participants with ankle brachial index >1.4 only as well as in subgroups defined

151 nary BPA levels (in tertiles) and PAD (ankle-brachial index < 0.9, n = 63) using logistic regression

152 achial index was used to diagnose PAD (ankle-brachial index </= 0.9).

153 nts were enrolled based on an abnormal ankle-brachial index </=0.80 or a previous lower extremity rev

154 Patients age 35 to 85 years with an ankle-brachial index </=0.95 and without clinically recognized

155 Toe brachial index <0.7 is more sensitive in diagnosing occl

156 g dampening was 43.6% sensitive, whereas toe brachial index <0.7 was 89.7% sensitive in diagnosing oc

157 Toe brachial index <0.7 was found in 75 of 83 (90.4%) limbs.

158 ine Rutherford category 4 to 6, and an ankle-brachial index <0.8.

159 Incident PAD was determined by an ankle-brachial index <0.9 assessed at 2 subsequent examination

160 ipants were free of PAD, defined as an ankle brachial index <0.9 or >1.4 at baseline, and had complet

161 0 cases of incident PAD, defined as an ankle brachial index <0.9 or >1.4, were identified.

162 ntile for age, sex, and ethnicity; and ankle-brachial index <0.9.

163 lative incidence of PAD, defined by an ankle brachial index <0.90 or a confirmed PAD event, with deat

164 95% CI 1.1-3.2, P=0.03), and baseline ankle-brachial index <=0.60 (HR 1.3 per 0.10 decrease, 95% CI

165 Enrollment criteria included an ankle-brachial index <=0.80 or previous lower extremity revasc

166 .06; 95% CI: -0.17, 0.03; P = .20), or ankle-brachial index (0.03; 95% CI: -0.08, 0.14; P = .57).

167 wide association studies (GWAS) of the ankle brachial index (ABI) and PAD (defined as an ABI < 0.90)

168 arteries (PCA) to those with a normal ankle-brachial index (ABI) and those with peripheral arterial

169 wed the evidence on the use of resting ankle-brachial index (ABI) as a screening test for PAD or as a

170 free of known cardiovascular (CVD) had ankle brachial index (ABI) assessment of their bilateral dorsa

171 ve test for diagnosis of LE-PAD is the ankle-brachial index (ABI) at rest and typically an ABI </= 0.

172 etermine whether use of an alternative ankle-brachial index (ABI) calculation method improves mortali

173 efined peripheral artery disease as an ankle brachial index (ABI) lower than or equal to 0.90.

174 Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone pr

175 y genetic variants associated with the ankle-brachial index (ABI), a noninvasive measure of PAD, we c

176 and changes in circulating PC levels, ankle brachial index (ABI), and walking impairment questionnai

177 of plaque, intima media thickness and ankle-brachial index (ABI), for N = 549.

178 ronary artery calcium (CAC) score, the ankle-brachial index (ABI), high-sensitivity C-reactive protei

179 e arsenic exposure and incident PAD by ankle brachial index (ABI).

180 ity were established by the use of the ankle-brachial index (ABI).

181 VM index, relative wall thickness, and ankle-brachial index (all P <0.01).

182 without B-type natriuretic peptide and ankle-brachial index (C statistic, 0.79; 95% CI, 0.75-0.83 [re

183 ctors, B-type natriuretic peptide, and ankle-brachial index (model 6) yielded modest improvement over

184 ith carotid intima-media thickness and ankle-brachial index (two other measures of subclinical athero

185 PAD was defined based on an ankle.brachial index .0.90.

186 cipants with PAD, independently of the ankle-brachial index and other confounders.

187 The sensitivity of toe brachial index and pulse volume recording to predict tib

188 ference in pain-free walking distance, ankle-brachial index and quality of life was found during long

189 , 2.6 (95% CI, 1.4-4.8), and 39.2; for ankle-brachial index criteria, 0.6%, 9%, 5%, 2.3 (95% CI, 0.6-

190 mpared with patients enrolled based on ankle-brachial index criteria.

191 ed with patients enrolled based on the ankle-brachial index criterion.

192 ne cadmium, potential confounders, and ankle brachial index determinations in the follow-up examinati

193 f poorer cognitive performance were an ankle brachial index greater than 1.30 (OR, 18.56 [95% CI, 2.9

194 ect measures of arterial stiffness, an ankle brachial index greater than 1.30 and increased blood pre

195 Moreover, patients with lower ankle-brachial index had (1) a more delayed reactive hyperemia

196 C-reactive protein <2 mg/L and normal ankle-brachial index had DLRs >0.80.

197 aseline atrial fibrillation, and lower ankle-brachial index identify peripheral artery disease patien

198 than carotid intima-media thickness or ankle-brachial index in subjects without and with CKD (HR, 1.6

199 The ankle-brachial index in the Viabahn group significantly increa

200 artery disease had to be defined as an ankle-brachial index lower than or equal to 0.90.

201 Ankle brachial index measurement was performed at the baseline

202 Of these patients, 47.5% underwent ankle-brachial index measurement, 38.7% duplex ultrasound, 31.

203 ) had a history of claudication and an ankle-brachial index of <0.85 or prior revascularization for l

204 y had intermittent claudication and an ankle brachial index of <0.85, or if they had a prior peripher

205 74.4 (6.6) years, and had a mean (SD) ankle brachial index of 0.67 (0.18).

206 ascular obstruction of 50% or greater, ankle-brachial index of less than 0.90, or physician-diagnosed

207 %), or coronary artery disease with an ankle-brachial index of less than 0.90.

208 protein, family history of ASCVD, and ankle-brachial index recommendations by the American College o

209 ical limb ischemia and noncompressible ankle brachial index results, the prevalence of occlusive tibi

210 proximately 20% of patients undergoing ankle brachial index testing for critical limb ischemia have n

211 hial flow-mediated dilation was 0.024, ankle-brachial index was 0.036, carotid intima-media thickness

212 73% were male, and the median baseline ankle-brachial index was 0.78.

213 The ankle-brachial index was used to diagnose PAD (ankle-brachial

214 Creatinine, age, and ankle-brachial index were among the top predictors of atrial f

215 al revascularization, smoking, and the ankle-brachial index were predictive of ALI.

216 ntimal medial thickness, stenosis, and ankle brachial index) and risk of dementia, CHD, and total mor

217 ction, microalbuminuria, and a reduced ankle-brachial index) in 2680 Framingham Study participants (m

218 n <50%, and peripheral artery disease (ankle-brachial index, <0.90).

219 d (mean age, 72.3 years [+/-7.1]; mean ankle brachial index, 0.66 [+/-0.15]), 40 (91%) completed foll

220 Of 125 limbs with noncompressible ankle brachial index, 72 (57.6%) anterior tibial and 80 (64%)

221 M index, relative wall thickness, CAC, ankle-brachial index, and cIMT were more abnormal across categ

222 ion, including the ankle-brachial index, toe-brachial index, and other perfusion technologies.

223 ain score, pain-free walking distance, ankle-brachial index, and transcutaneous oxygen measurements (

224 y outcomes quality of life, rest pain, ankle-brachial index, and transcutaneous oxygen pressure impro

225 rtality, adjusting for age, sex, race, ankle-brachial index, body mass index, smoking, comorbidities,

226 lcium, carotid intima-media thickness, ankle-brachial index, brachial flow-mediated dilation, high-se

227 ubclinical disease measures, including ankle-brachial index, carotid intimal-medial thickness, and ec

228 operatively with physical examination, ankle brachial index, duplex, and a quality-of-life questionna

229 Coronary artery calcium, ankle-brachial index, high-sensitivity CRP, and family history

230 Coronary artery calcium, ankle-brachial index, high-sensitivity CRP, and family history

231 n of carotid intima-media thickness or ankle-brachial index, inclusion of the coronary artery calcium

232 Cell therapy significantly increased ankle brachial index, increased transcutaneous oxygen tension,

233 flexion inversely correlated with the ankle-brachial index, indicating that patients with more sever

234 p was found between floccular fossa size and brachial index, no significant relationship was found be

235 erences in pain-free walking distance, ankle-brachial index, quality of life, progression to critical

236 Improvements in ankle-brachial index, Rutherford class, and quality of life we

237 but noninvasive measures, such as the ankle-brachial index, show that asymptomatic PAD is several ti

238 d for age, sex, race, body mass index, ankle-brachial index, smoking, physical activity, and comorbid

239 otid plaque, no family history, normal ankle-brachial index, test result <25th percentile (carotid in

240 sment of limb perfusion, including the ankle-brachial index, toe-brachial index, and other perfusion

241 ts) precisely estimated the changes in ankle brachial index, transcutaneous oxygen tension, rest pain

242 tid artery intima-media thickness, and ankle-brachial index.

243 l revascularization and lower baseline ankle-brachial index.

244 ted States were evaluated by screening ankle brachial indices <0.9 for peripheral artery disease (PAD

245 atrienoic acids and NO was assessed with the brachial infusion of inhibitors of cytochrome P450 epoxy

246 ibution and consensus sequences in axillary, brachial, inguinal, and mesenteric LNs were virtually id

247 scular conductance (FVC; Doppler ultrasound, brachial intra-arterial pressure via catheter) to local

248 Increased T2 signal intensity and volume of brachial nerve roots do not exclude a diagnosis of ALS a

249 The association between brachial NO-dependent flow-mediated dilation (FMD) and c

250 oral and external iliac arteries but not the brachial or common carotid arteries and not correlated s

251 romatin domains, leading to specification of brachial or thoracic spinal identity.

252 ted in 10 patients who had been referred for brachial plexopathy at 3.0 T.

253 re survivors experience chronic pain such as brachial plexopathy from upper extremity suspension or l

254 seven with Guillain-Barre syndrome, one with brachial plexopathy, six of eight making a partial and o

255 Protocol I aimed to develop the vascularized brachial plexus allotransplantation (VBP-allo) model.

256 al study, we assessed the feasibility of rat brachial plexus allotransplantation and analyzed its fun

257 Vascularized brachial plexus allotransplantation could offer the best

258 demonstrated a useful vascularized complete brachial plexus allotransplantation rodent model with su

259 ized protocol of brachial plexus MR imaging, brachial plexus and limb-girdle muscle abnormalities wer

260 Axons traveling within the brachial plexus are responsible for the dexterous contro

261 es and can be used for MR neurography of the brachial plexus at 3.0 T.

262 or outpatient shoulder surgery, interscalene brachial plexus block (ISBPB) is currently the most pref

263 ocaine injected subcutaneously) or regional (brachial plexus block [BPB]) anaesthesia (0.5% L-bupivac

264 AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidoc

265 praclavicular, infraclavicular, and axillary brachial plexus blocks, however, are all commonly used a

266 Background Traumatic brachial plexus injuries affect 1% of patients involved

267 Brachial plexus injuries are devastating.

268 Overall, 72% of patients with brachial plexus injuries had at least one root avulsion

269 lts with traumatic nonpenetrating unilateral brachial plexus injuries were included.

270 MRI is the best test for traumatic brachial plexus injuries, although its ability to differ

271 sing root avulsions in adults with traumatic brachial plexus injuries.

272 Neonatal brachial plexus injury (NBPI) causes disabling and incur

273 Using time-lapse imaging in an obstetrical brachial plexus injury (OBPI) model, we show that microg

274 ations were urinary retention (4), transient brachial plexus injury, dislodgement of an intrauterine

275 as well as major nerves originating from the brachial plexus innervating the arm and hand) was perfor

276 By using an optimized protocol of brachial plexus MR imaging, brachial plexus and limb-gir

277 n in its role in the management of obstetric brachial plexus palsy, with investigation within 1 month

278 ers modest diagnostic accuracy for traumatic brachial plexus root avulsion(s), and early surgical exp

279 A free vascularized brachial plexus with a chimeric compound skin paddle fla

280 e magnetic resonance (MR) neurography of the brachial plexus with robust fat and blood suppression fo

281 There were 3 patients with brachial plexus-related symptoms all consisting of C8 ti

282 patients on hemodialysis, we measured ankle-brachial pressure index (ABix) and evaluated mineral and

283 The diagnostic performance of ankle-brachial pressure index (ABPI), toe-brachial pressure in

284 of ankle-brachial pressure index (ABPI), toe-brachial pressure index (TBPI), transcutaneous pressure

285 Ankle brachial pressure index and carotid intima-medial thickn

286 Ankle-brachial pressure index increased from 0.75 to 0.98 (P <

287 r older with a venous leg ulcer and an ankle brachial pressure index of at least 0.8, and were tolera

288 Beyond brachial pressure measurements, central hemodynamic para

289 ardiovascular magnetic resonance imaging and brachial pressure.

290 Brachial pulse pressure (bPP), aoPP, and all measures of

291 measuring flow-mediated vasodilation (FMD), brachial pulse wave velocity (bPWV), circulating angioge

292 Central (carotid) to peripheral (brachial) pulse pressure amplification (PPA) was calcula

293 easured aortic pulse wave velocity (PWV) and brachial PWV to evaluate the stiffness gradient [(brachi

294 ial PWV to evaluate the stiffness gradient [(brachial PWV/aortic PWV)(0.5)] and ascending aortic and

295 On the head, they are confined to discrete brachial regions referred to as "arm pillars" that expan

296 Brachial stiffness, augmentation index, and systemic art

297 Brachial systolic and pulse pressure were also independe

298 The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 +/- 35 to 138 +/- 30 and

299 reased difference between the left and right brachial systolic pressures.

300 decreased endothelial function according to brachial ultrasound results.